Development of PROSTVAC immunotherapy in prostate cancer

Future Oncology

Volumn 11, Issue 15, 2015, Pages 2137-2148

  Singh, Parminder ^a   Pal, Sumanta K ^b   Alex, Anitha ^c   Agarwal, Neeraj ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

pox virus immunotherapy; prostate cancer; PROSTVAC

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; IPILIMUMAB; PLACEBO; POXVIRUS VECTOR; PROSTATE SPECIFIC ANTIGEN; RILIMOGENE GALVACIREPVEC; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; CANCER VACCINE; MONOCLONAL ANTIBODY;

ABLATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FOWLPOX; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; TRANSGENE; VACCINIA; CLINICAL TRIAL (TOPIC); GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROSTATIC NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84938488864     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.120     Document Type: Article

References (41)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5-29 (2015
2. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321(7), 419-424 (1989
3. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004
4. Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004
5. Agarwal N, Padmanabh S, Vogelzang NJ. Development of novel immune interventions for prostate cancer. Clin. Genitourin Cancer 10(2), 84-92 (2012
6. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a Poxviralbased PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099-1105 (2010
7. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 81(6), 1297-1302 (2013
8. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 26(32), 5275-5283 (2008
9. Reese Z, Straubhar A, Pal SK, Agarwal N. Ipilimumab in the treatment of prostate cancer. Future Oncol. 11(1), 27-37 (2015
10. Kwon ED, Drake CG, Scher HI et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, Phase 3 trial. Lancet Oncol. 15(7), 700-712 (2014
11. Gulley JL, Madan RA, Tsang KY et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol. Res. 2(2), 133-141 (2014
12. Madan RA, Heery CR, Gulley JL. Poxviralbased vaccine elicits immunologic responses in prostate cancer patients. Oncoimmunology 3, e28611 (2014
13. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat. Immunol. 10(8), 580-593 (2010
14. Mandl SJ, Rountree RB, Dela Cruz TB et al. Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy. J. Immunother. Cancer 2(1), 34 (2014
15. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59(22), 5800-5807 (1999). (PSA) for effective immunotherapy regimen
16. Gulley J, Chen AP, Dahut W et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53(2), 109-117 (2002
17. Kaufman HL, Wang W, Manola J et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22(11), 2122-2132 (2004
18. Levy B, Panicalli D, Marshall J. TRICOM: enhanced vaccines as anticancer therapy. Expert Rev. Vaccines 3(4), 397-402 (2004
19. DiPaola RS, Plante M, Kaufman H et al. A Phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM in patients with prostate cancer. J. Transl. Med. 4, 1 (2006
20. Arlen PM, Skarupa L, Pazdur M et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J. Urol. 178(4 Pt 1), 1515-1520 (2007
21. Gulley JL, Arlen PM, Madan RA et al. Immunologic and prognostic factors associated with overall survival employing a poxviralbased PSA vaccine in metastatic castrateresistant prostate cancer. Cancer Immunol. Immunother. 59(5), 663-674 (2010
22. Madan RA, Mohebtash M, Arlen PM et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A Phase 1 dose-escalation trial. Lancet Oncol. 13(5), 501-508 (2012
23. Singh H, Madan RA, Dahut WL et al. Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer. J. Clin. Oncol. 33(Suppl 7.), Abstract 172 (2015
24. Gulley JL, Arlen PM, Bastian A et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11(9), 3353-3362 (2005
25. Heery CR, Madan RM, Bilusic M et al. A Phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. J. Clin. Oncol. 31(Suppl. 6), Abstract 102 (2013
26. Arlen PM, Gulley JL, Parker C et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. J. Clin. Oncol. 12(4), 1260-1269 (2006
27. Madan RA, Gulley JL, Schlom J et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. J. Clin. Oncol. 14(14), 4526-4531 (2008
28. Bilusic M, Gulley JL, Heery C et al. A randomized Phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC) J. Clin. Oncol. 29(Suppl. 7), Abstract 163 (2011
29. Chakraborty M, Abrams SI, Camphausen K et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol. (Baltimore, Md. 1950) 170(12), 6338-6347 (2003
30. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64(12), 4328-4337 (2004
31. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13(9), 1050-1059 (2007
32. Sheard MA, Vojtesek B, Janakova L, Kovarik J, Zaloudik J. Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int. J. Cancer 73(5), 757-762 (1997
33. Ramakrishnan R, Assudani D, Nagaraj S et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 120(4), 1111-1124 (2010
34. Lesterhuis WJ, Punt, , Cornelis J A, Hato SV et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J. Clin. Invest. 121(8), 3100-3108 (2011
35. Nowak AK, Lake RA, Marzo AL et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 170(10), 4905-4913 (2003
36. Nowak AK, Robinson, , Bruce W S, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 62(8), 2353-2358 (2002
37. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin. Cancer Res. 14(11), 3536-3544 (2008
38. Windmill KF, Lee VW. Effects of castration on the lymphocytes of the thymus, spleen and lymph nodes. Tissue Cell 30(1), 104-111 (1998
39. Goldberg GL, Sutherland JS, Hammet MV et al. Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation. Transplantation 80(11), 1604-1613 (2005
40. Mercader M, Bodner BK, Moser MT et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl. Acad. Sci. USA 98(25), 14565-14570 (2001
41. Kim JW, Marte JL, Singh NK et al. Safety profile of recombinant poxviral TRICOM vaccines. J. Clin. Oncol. 31(Suppl), Abstract e16036 (2013